# Compare: BPC-157 vs Ipamorelin vs Retatrutide vs Thymosin Alpha-1 — Peptide Biotechnology

> A structured comparison of BPC-157, Ipamorelin, Retatrutide and Thymosin Alpha-1 by signaling class, mechanism, evidence maturity, regulatory status and WADA status. Part of Research Peptide Fundamentals.

BPC-157, Ipamorelin, Retatrutide and Thymosin Alpha-1 — lined up by class, mechanism, human evidence and regulatory status.

## The short version

Four research peptides, four distinct signaling strategies. BPC-157 is a cytoprotective peptide working through angiogenesis at the tissue level. Ipamorelin is a secretagogue that triggers pulsatile growth hormone release from the pituitary. Retatrutide is an investigational incretin triple-agonist managing appetite, glucose metabolism and energy expenditure via three simultaneous receptor targets. Thymosin Alpha-1 is an immune modulator shaping T-cell education and dendritic-cell maturation at the innate-adaptive interface.

They share almost no mechanism. They share a class label (research peptides) and a regulatory reality (none is an FDA-approved drug in general use). The table and notes below make those distinctions concrete.

## Head-to-head comparison

| Peptide | Class | Primary mechanism | What it is primarily studied for | Best human evidence | Regulatory status | WADA status |
|---|---|---|---|---|---|---|
| [BPC-157](/bpc-157) | Cytoprotective | VEGFR2 angiogenesis + nitric-oxide signaling | Tissue repair (tendon, gut, muscle) in animal models | First-in-human safety pilot (n=2); narrative reviews only [1][2] | Not approved anywhere; 503A compounding ineligible (FDA) | Prohibited (S0, all times) |
| [Ipamorelin](/ipamorelin) | GH Secretagogue | GHS-R1a agonism → pituitary GH pulse | GH axis stimulation, preclinical bone and body composition | Human PK/PD study (n=8); Phase 2 RCT failed primary endpoint (n=114) [8][9] | Never approved; removed from 503A Category 2 (2024) | Prohibited (S2, all times) |
| [Retatrutide](/retatrutide) | Incretin Triple-Agonist | GLP-1R + GIPR + GCGR simultaneous agonism | Obesity, type 2 diabetes, metabolic liver disease | Phase 2 trials (338–338 adults, 48 wk obesity; 281 adults, 36 wk T2D) [16][17] | Investigational; Phase 3 ongoing; not approved | Not specifically prohibited (verify current WADA list) |
| [Thymosin Alpha-1](/thymosin-alpha-1) | Immune Modulator | TLR2/TLR9 → dendritic-cell maturation + Th1 polarization | Chronic hepatitis, sepsis, cancer immunotherapy adjuvant | Multiple RCTs including Phase 3 sepsis trial (n=1,106; null) [18][22] | Approved as drug in 35+ countries; not FDA-approved in the US | Not specifically prohibited (verify current WADA list) |

## What the comparison reveals

**Evidence maturity varies enormously.** Thymosin Alpha-1 has the deepest clinical record — decades of trials across hepatitis, sepsis and cancer contexts — yet its most recent, most rigorous test (a 2025 Phase 3 sepsis RCT) was null [18]. Retatrutide has the youngest and most prospective evidence: large Phase 2 RCTs with striking weight-loss numbers, but Phase 3 still ongoing [13]. Ipamorelin has one failed Phase 2 trial and one human PK study from 1999 as its entire controlled human dataset [8][9]. BPC-157 has the preclinical depth and the shallowest human file: two safety-pilot subjects as of the most recent review [1][2].

**Mechanism does not predict regulatory approval.** All four have coherent, published mechanistic rationales. None is an approved FDA drug for general use. Mechanism and preclinical promise do not translate automatically into approval-grade safety and efficacy — the histories of ipamorelin and thymosin alpha-1, each of which has had controlled human trials, underscore this point [8][18].

**WADA status matters for athletes.** BPC-157 and Ipamorelin are both prohibited in sport at all times. Athletes should verify Retatrutide and Thymosin Alpha-1 status against the current WADA Prohibited List before assuming they are permissible.

**Gray-market quality risk applies to all four.** Research-grade material purchased outside a clinical trial context has no guaranteed identity, purity or sterility for any of these compounds, regardless of how well-established the molecule's pharmacology is in the formal literature.

---

A desk for reading, not prescribing — literature summaries of research peptide biology, cited to the primary source.